Chargement de l’entreprise
Just reported
Q3 2026 results
From ZAI LAB's results release of 5 novembre 2026; its quarterly report has since been filed.
Revenue
Actual
108,2M $US
-6,8 % y/y
+1,8 % q/qGuided
—
No guide given
EPS, GAAP
Actual
-0,40 $US
Guided
—
No guide given
Operating income, GAAP
Actual
-63M $US
Guided
—
No guide given
Set against the company's own guidance and the same quarter a year earlier, not analysts' estimates, which we do not hold. Adjusted figures are the company's own non-GAAP measures, as stated in the release.
The full earnings report →Keep exploring
The themes ZAI LAB is part of, the highest-graded companies in its industry, and the companies in its sector whose grade rose recently.
Highest-graded in Biotechnology
Graded A or B and worth $2B or more: A first, then the largest.
ONCBeone Medicines Ltd.47,5B $USA+
EXELExelixis, Inc.17B $USA+
JAZZJazz Pharmaceuticals plc15,4B $USA
HALOHalozyme Therapeutics, Inc.11,5B $USA+
TECHBIO-Techne Corp11,4B $USA+
Grade rose recently in Healthcare
Rose to A or B on a filing in the last 90 days, worth $2B or more: largest first.
DHRDanaher Corporation21 oct. 2026CBGraded C, now B
MCKMckesson Corporation4 nov. 2026BAGraded B, now A
CVSCVS Health Corp4 nov. 2026BAGraded B, now A
EWEdwards Lifesciences Corporation4 nov. 2026BAGraded B, now A
BIIBBiogen Inc.28 oct. 2026BAGraded B, now A
Construit à partir des documents déposés par ZAI LAB Limited auprès de la Securities and Exchange Commission (SEC), le gendarme boursier américain. Les chiffres sont tels que publiés, l’historique par action étant retraité sur la base d’actions d’aujourd’hui. Ceci décrit une entreprise — ce n’est pas un conseil en investissement ni une recommandation d’acheter ou de vendre.
